Orally administered sulphonylurea drugs, commonly used to treat type 2 diabetes, close the KATP channel by an ATP independent route and thus increase insulin secretion, although the required dose is frequently considerably higher. The gene discussed is INS; the disease is type 2 diabetes mellitus.